Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome-Strategies for In Vivo Administration: Part-II

Detalhes bibliográficos
Autor(a) principal: Vieira, Raquel
Data de Publicação: 2019
Outros Autores: Souto, Selma B., Sánchez-López, Elena, Machado, Ana López, Severino, Patrícia, Jose, Sajan, Santini, Antonello, Fortuna, Ana, García, Maria Luisa, Souto, Eliana B.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10316/107084
https://doi.org/10.3390/jcm8091332
Resumo: Diabetes is a complex disease characterized by hyperglycemia, together with polyuria, polydipsia, and polyphagia. While Type 1 diabetes mellitus (T1DM) results from genetic, environmental, or immune dysfunction factors leading to pancreatic β-cell destruction depriving the organism from endogenous insulin, Type 2 diabetes mellitus (T2DM) is characterized by peripheral insulin resistance. Depending on the type of diabetes mellitus and drug mechanism to study, the animal model should be carefully selected among the wide variety of the currently available ones. This review discusses the most common animal models currently employed to study T1DM and T2DM. Moreover, an overview on the administration routes that could be used is also discussed.
id RCAP_06e3bc8a19d3da5d5c25ef4d76f6bb51
oai_identifier_str oai:estudogeral.uc.pt:10316/107084
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome-Strategies for In Vivo Administration: Part-IIdiabetes mellitusanimal modelsin vivoadministration routesDiabetes is a complex disease characterized by hyperglycemia, together with polyuria, polydipsia, and polyphagia. While Type 1 diabetes mellitus (T1DM) results from genetic, environmental, or immune dysfunction factors leading to pancreatic β-cell destruction depriving the organism from endogenous insulin, Type 2 diabetes mellitus (T2DM) is characterized by peripheral insulin resistance. Depending on the type of diabetes mellitus and drug mechanism to study, the animal model should be carefully selected among the wide variety of the currently available ones. This review discusses the most common animal models currently employed to study T1DM and T2DM. Moreover, an overview on the administration routes that could be used is also discussed.MDPI2019-08-28info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://hdl.handle.net/10316/107084http://hdl.handle.net/10316/107084https://doi.org/10.3390/jcm8091332eng2077-0383Vieira, RaquelSouto, Selma B.Sánchez-López, ElenaMachado, Ana LópezSeverino, PatríciaJose, SajanSantini, AntonelloFortuna, AnaGarcía, Maria LuisaSouto, Eliana B.info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-05-11T12:15:05Zoai:estudogeral.uc.pt:10316/107084Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T21:23:27.474593Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome-Strategies for In Vivo Administration: Part-II
title Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome-Strategies for In Vivo Administration: Part-II
spellingShingle Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome-Strategies for In Vivo Administration: Part-II
Vieira, Raquel
diabetes mellitus
animal models
in vivo
administration routes
title_short Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome-Strategies for In Vivo Administration: Part-II
title_full Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome-Strategies for In Vivo Administration: Part-II
title_fullStr Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome-Strategies for In Vivo Administration: Part-II
title_full_unstemmed Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome-Strategies for In Vivo Administration: Part-II
title_sort Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome-Strategies for In Vivo Administration: Part-II
author Vieira, Raquel
author_facet Vieira, Raquel
Souto, Selma B.
Sánchez-López, Elena
Machado, Ana López
Severino, Patrícia
Jose, Sajan
Santini, Antonello
Fortuna, Ana
García, Maria Luisa
Souto, Eliana B.
author_role author
author2 Souto, Selma B.
Sánchez-López, Elena
Machado, Ana López
Severino, Patrícia
Jose, Sajan
Santini, Antonello
Fortuna, Ana
García, Maria Luisa
Souto, Eliana B.
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Vieira, Raquel
Souto, Selma B.
Sánchez-López, Elena
Machado, Ana López
Severino, Patrícia
Jose, Sajan
Santini, Antonello
Fortuna, Ana
García, Maria Luisa
Souto, Eliana B.
dc.subject.por.fl_str_mv diabetes mellitus
animal models
in vivo
administration routes
topic diabetes mellitus
animal models
in vivo
administration routes
description Diabetes is a complex disease characterized by hyperglycemia, together with polyuria, polydipsia, and polyphagia. While Type 1 diabetes mellitus (T1DM) results from genetic, environmental, or immune dysfunction factors leading to pancreatic β-cell destruction depriving the organism from endogenous insulin, Type 2 diabetes mellitus (T2DM) is characterized by peripheral insulin resistance. Depending on the type of diabetes mellitus and drug mechanism to study, the animal model should be carefully selected among the wide variety of the currently available ones. This review discusses the most common animal models currently employed to study T1DM and T2DM. Moreover, an overview on the administration routes that could be used is also discussed.
publishDate 2019
dc.date.none.fl_str_mv 2019-08-28
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10316/107084
http://hdl.handle.net/10316/107084
https://doi.org/10.3390/jcm8091332
url http://hdl.handle.net/10316/107084
https://doi.org/10.3390/jcm8091332
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 2077-0383
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799134121540190208

Registros relacionados